<code id='2BB886E034'></code><style id='2BB886E034'></style>
    • <acronym id='2BB886E034'></acronym>
      <center id='2BB886E034'><center id='2BB886E034'><tfoot id='2BB886E034'></tfoot></center><abbr id='2BB886E034'><dir id='2BB886E034'><tfoot id='2BB886E034'></tfoot><noframes id='2BB886E034'>

    • <optgroup id='2BB886E034'><strike id='2BB886E034'><sup id='2BB886E034'></sup></strike><code id='2BB886E034'></code></optgroup>
        1. <b id='2BB886E034'><label id='2BB886E034'><select id='2BB886E034'><dt id='2BB886E034'><span id='2BB886E034'></span></dt></select></label></b><u id='2BB886E034'></u>
          <i id='2BB886E034'><strike id='2BB886E034'><tt id='2BB886E034'><pre id='2BB886E034'></pre></tt></strike></i>

          hotspot

          hotspot

          author:comprehensive    Page View:9881
          Two people stare at a keyhole in a human head in between them, as the short-haired person on the left holds a key — first opinion coverage from STAT
          Adobe

          In many ways, psychiatry is still flying blind. People experiencing mental health conditions are prescribed various drugs until one (or a combination) finally works — a painful process that can take years. As a psychiatrist and neuroscientist, I became increasingly impatient and frustrated with this ineffective way of treating patients. This guided the core question behind my research: Can biology explain how people with the same psychiatric disorder respond differently to the same treatment?

          Since I first began exploring this question more than a decade ago, mental illness has become a global epidemic. Despite significant efforts, progress in psychiatric drug development has remained disappointingly slow. There have been a few notable approvals in recent years, and a renewal of interest by Big Pharma, following a retreat from psychiatric research in the mid to late 2000s. But the landscape remains predominantly marked by failures and a dry drug development pipeline. Approved drugs follow the same pattern of prescribing via guesswork, with most patients not responding to a given drug. This cycle of trial-and-error drug development producing trial-and-error treatment arises from a simple source: We have not systematized a process for learning from our failures and successes.

          advertisement

          Related: A ‘renaissance in neuroscience’ could deliver a fresh crop of psychiatric medicines

          For example, take depression: While the rise of selective serotonin reuptake inhibitors (SSRIs) in the 1980s and 1990s seemed to provide a solution, seminal studies in the 2000s exposed fundamental limitations of our treatment options. Antidepressants are widely prescribed, but their efficacy relative to placebo is modest.

          Get unlimited access to award-winning journalism and exclusive events.

          Subscribe Log In

          explore

          DIEP, the 'gold standard' of breast reconstruction, is under threat
          DIEP, the 'gold standard' of breast reconstruction, is under threat

          AdobeIn1983,Iflewhomefromcollegetobewithmymotherasshewokeupfromamastectomy.Sheoptedoutofbreastrecons

          read more
          Why liver experts renamed NASH to MASH, and NAFLD to MASLD
          Why liver experts renamed NASH to MASH, and NAFLD to MASLD

          AdobeAslateofliverdiseasesgotarebrandthisyear.Expertshopethechangecangeneratemoreconversation—andres

          read more
          Biden outlines 'new path' to provide student loan relief after Supreme Court rejection
          Biden outlines 'new path' to provide student loan relief after Supreme Court rejection

          6:16PresidentJoeBidenspeaksintheRooseveltRoomoftheWhiteHouse,June30,2023.EvanVucci/APPresidentJoeBid

          read more

          For Medicare Advantage, Democrats want stronger protections around AI

          Sen.ElizabethWarren(D-Mass.)KentNishimura/GettyImagesSenateDemocratsonThursdaysaidMedicareshouldtake